Erratum: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis [J Cancer Res Clin Oncol, DOI 10.1007/s00432-014-1709-0];Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 11, 2014, Pages 1901-1909

  Wang, Huan ^a   Huang, Jing ^b   Yu, Xiaojin ^c   Han, Shuhua ^b   Yan, Xing ^a   Sun, Siqing ^b   Zhu, Xiaoli ^b  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

Author keywords

EGFR; EGFR TKIs; Meta analysis; NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; GENE DELETION; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; RISK; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK; TREATMENT OUTCOME;

EID: 84919499953     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1825-x     Document Type: Erratum

References (34)

1. Asahina H, Yamazaki K, Kinoshita I et al (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95(8):998–1004
2. Cappuzzo F, Ligorio C, Jänne PA et al (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non–small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25(16):2248–2255
3. Chou TY, Chiu CH, Li LH et al (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11(10):3750–3757
4. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21(12):2237–2246
5. Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874
6. Gao G, Ren S, Li A et al (2012) Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 131(5):E822–E829
7. Hirsch FR, Varella-Garcia M, Cappuzzo F et al (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18(4):752–760
8. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13
9. Ichihara S, Toyooka S, Fujiwara Y et al (2007) The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120(6):1239–1247
10. Jackman DM, Yeap BY, Sequist LV et al (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12(13):3908–3914
11. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
12. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388
13. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128
14. Morita S, Okamoto I, Kobayashi K et al (2009) Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15(13):4493–4498
15. NCCN clinical practice guidelines in oncology: non-small cell lung cancer version 2. 2014
16. Pallis AG, Voutsina A, Kalikaki A et al (2007) ‘Classical’but not ‘other’mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 97(11):1560–1566
17. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta analyses of the published literature for survival endpoints. Stat Med 17:2815–2834
18. Paz-Ares L, Soulières D, Melezínek I et al (2010) Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 14(1–2):51–69
19. Riely GJ, Pao W, Pham D et al (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839–844
20. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967
21. Sequist LV, Martins RG, Spigel D et al (2008) First-line gefitinib in patients with advanced non–small-cell lung cancer harboring somatic EGFR mutations[J]. J Clin Oncol 26(15):2442–2449
22. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta analyses. Eur J Epidemiol 25(9):603–605
23. Sugio K, Uramoto H, Onitsuka T et al (2009) Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 64(3):314–318
24. Sunaga N, Tomizawa Y, Yanagitani N et al (2007) Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56(3):383–389
25. Sutani A, Nagai Y, Udagawa K et al (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95(11):1483–1489
26. Takano T, Ohe Y, Tsuta K et al (2007) Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non–small cell lung cancer treated with gefitinib. Clin Cancer Res 13(18):5385–5390
27. Tamura K, Okamoto I, Kashii T et al (2008) Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98(5):907–914
28. Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353(2):133–144
29. Wells GA, Shea B, O’ Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses, [2012-06-15]
30. Wu M et al (2010) EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 67(3):343–347
31. Xu JM, Han Y, Duan HQ et al (2009) EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol 135(6):771–782
32. Yang CH, Yu CJ, Shih JY et al (2008) Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non–small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26(16):2745–2753
33. Yoshida K, Yatabe Y, Park JY et al (2007) Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2(1):22–28
34. 马宇翔, 黄岩, 赵洪云, 等. 晚期 EGFR 突变型非小 细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析. 中国肺癌杂志, 2013, 16(4):203–210